Reactive intermediates formation and bioactivation pathways of spebrutinib revealed by LC-MS/MS: In vitro and in silico metabolic study

Spebrutinib is a new Bruton tyrosine kinase inhibitor developed by Avila Therapeutics and Celgene. Spebrutinib (SPB) is currently in phase Ib clinical trials for the treatment of lymphoma in the United States. Preliminary in-silico studies were first performed to predict susceptible sites of metabol...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsibaee, Aishah M., Aljohar, Haya I., Attwa, Mohamed W., Abdelhameed, Ali Saber, Kadi, Adnan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361234/
https://www.ncbi.nlm.nih.gov/pubmed/37484253
http://dx.doi.org/10.1016/j.heliyon.2023.e17058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361234/
https://www.ncbi.nlm.nih.gov/pubmed/37484253
http://dx.doi.org/10.1016/j.heliyon.2023.e17058

Ejemplares similares